Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Technologies Global Corp. (AVR)
Company Research
Source: GlobeNewswire
MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1. The late-breaking science was presented by Prof. Dr. Ole De Backer at the PCR London Valves conference in London, United Kingdom with simultaneous publication online in EuroIntervention - ‘Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli’ (DOI: 10.4244/EIJ-D-25-011
Show less
Read more
Impact Snapshot
Event Time:
AVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVR alerts
High impacting Anteris Technologies Global Corp. news events
Weekly update
A roundup of the hottest topics
AVR
News
- Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well [Yahoo! Finance]Yahoo! Finance
- Anteris Technologies Global (NASDAQ:AVR) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital RaisesGlobeNewswire
- Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common StockGlobeNewswire
- Medtronic to buy up to $90M stake in heart valve developer Anteris [Yahoo! Finance]Yahoo! Finance
AVR
Analyst Actions
- 1/23/26 - Lake Street Capital
AVR
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/29/26 - Form 3
- 1/23/26 - Form 424B3
- AVR's page on the SEC website